CAMBRIDGE, Mass., Aug. 28, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that Rogerio Vivaldi, president and chief executive officer of Minerva, will present at the Baird 2014 Health Care Conference on Thursday, September 4, 2014 at 1:25 p.m. EDT in New York City, NY.
A live audio webcast of the presentation will be available online from the investor relations section of the company's website at http://ir.minervaneurosciences.com. A replay of the presentation will be posted on the Minerva website approximately one hour after the event and will be available for 30 days following the presentation.
About Minerva
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neuropsychiatric diseases. Minerva is developing a portfolio of first-in-class proprietary compounds, including lead compound MIN-101, which is in Phase 2 trials for schizophrenia, and additional candidates targeting major depressive disorder (MDD), insomnia and other CNS disorders. Minerva's common stock is listed on the NASDAQ Global Market where it trades under the symbol "NERV." For more information, please visit
www.minervaneurosciences.com/.
CONTACT: Media Contact:
Jen Ringler
Berry & Company Public Relations
Tel: 212-253-8881
jringler@berrypr.com
Investor Contact:
Renee Leck
Stern Investor Relations
Tel: 212-362-1200
renee@sternir.com
Source:
Minerva Neurosciences, Inc
News Provided by Acquire Media
